BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32297906)

  • 1. Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy: A Systematic Review.
    Sonbol MB; Halfdanarson TR; Hilal T
    JAMA Oncol; 2020 Jul; 6(7):1086-1092. PubMed ID: 32297906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series.
    Goncalves I; Burbury K; Michael M; Iravani A; Ravi Kumar AS; Akhurst T; Tiong IS; Blombery P; Hofman MS; Westerman D; Hicks RJ; Kong G
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1902-1910. PubMed ID: 31187162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloid neoplasms after chemotherapy and PRRT: myth and reality.
    Bodei L; Modlin IM; Luster M; Forrer F; Cremonesi M; Hicks RJ; Ezziddin S; Kidd M; Chiti A
    Endocr Relat Cancer; 2016 Aug; 23(8):C1-7. PubMed ID: 27353035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: prognostic parameters and overall survival.
    Chantadisai M; Kulkarni HR; Baum RP
    Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1390-1398. PubMed ID: 33247328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
    Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
    Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
    J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs.
    Kwekkeboom DJ; Krenning EP; Lebtahi R; Komminoth P; Kos-Kudła B; de Herder WW; Plöckinger U; ;
    Neuroendocrinology; 2009; 90(2):220-6. PubMed ID: 19713714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy.
    Yordanova A; Wicharz MM; Mayer K; Brossart P; Gonzalez-Carmona MA; Strassburg CP; Fimmers R; Essler M; Ahmadzadehfar H
    Clin Cancer Res; 2018 Oct; 24(19):4672-4679. PubMed ID: 29950352
    [No Abstract]   [Full Text] [Related]  

  • 9. Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience.
    Kesavan M; Turner JH
    Cancer Biother Radiopharm; 2016 Aug; 31(6):189-98. PubMed ID: 27419665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors.
    Ramage J; Naraev BG; Halfdanarson TR
    Semin Oncol; 2018 Aug; 45(4):236-248. PubMed ID: 30539715
    [No Abstract]   [Full Text] [Related]  

  • 11. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with
    Bergsma H; van Lom K; Raaijmakers MHGP; Konijnenberg M; Kam BLBLR; Teunissen JJM; de Herder WW; Krenning EP; Kwekkeboom DJ
    J Nucl Med; 2018 Mar; 59(3):452-458. PubMed ID: 28775205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GEPNETs update: Radionuclide therapy in neuroendocrine tumors.
    van der Zwan WA; Bodei L; Mueller-Brand J; de Herder WW; Kvols LK; Kwekkeboom DJ
    Eur J Endocrinol; 2015 Jan; 172(1):R1-8. PubMed ID: 25117465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage peptide receptor radionuclide therapy with [
    van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy of first and second series of peptide receptor radionuclide therapy in patients with neuroendocrine neoplasm: a cohort study.
    Zacho MD; Iversen P; Villadsen GE; Baunwall SMD; Arveschoug AK; Grønbaek H; Dam G
    Scand J Gastroenterol; 2021 Mar; 56(3):289-297. PubMed ID: 33470864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
    Carlsen EA; Fazio N; Granberg D; Grozinsky-Glasberg S; Ahmadzadehfar H; Grana CM; Zandee WT; Cwikla J; Walter MA; Oturai PS; Rinke A; Weaver A; Frilling A; Gritti S; Arveschoug AK; Meirovitz A; Knigge U; Sorbye H
    Endocr Relat Cancer; 2019 Feb; 26(2):227-239. PubMed ID: 30540557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy.
    de Visser M; Verwijnen SM; de Jong M
    Cancer Biother Radiopharm; 2008 Apr; 23(2):137-57. PubMed ID: 18454684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
    Parghane RV; Talole S; Prabhash K; Basu S
    Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy.
    Werner RA; Ilhan H; Lehner S; Papp L; Zsótér N; Schatka I; Muegge DO; Javadi MS; Higuchi T; Buck AK; Bartenstein P; Bengel F; Essler M; Lapa C; Bundschuh RA
    Mol Imaging Biol; 2019 Jun; 21(3):582-590. PubMed ID: 30014345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage peptide receptor radionuclide therapy in patients with progressive neuroendocrine tumors: a systematic review and meta-analysis.
    Kim YI
    Nucl Med Commun; 2021 Apr; 42(4):451-458. PubMed ID: 33346603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide receptor radionuclide therapy for advanced neuroendocrine tumors.
    Bodei L; Cremonesi M; Kidd M; Grana CM; Severi S; Modlin IM; Paganelli G
    Thorac Surg Clin; 2014 Aug; 24(3):333-49. PubMed ID: 25065935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.